Cellectar Biosciences, Inc. · NASDAQ:CLRB

Cellectar Biosciences — Imaging in 2020 (Jackson Hole, WY)

48 slides from Cellectar Biosciences's conference presentation, Oct 3, 2012

  1. Slide 1: Molecular Diapeutics: Phospholipid Ether Analogs for Cancer Detection and Treatment

    Molecular Diapeutics: Phospholipid Ether Analogs for Broad Spectrum Cancer and Cancer Stem Cell Detection and Treatment Jamey Weichert, PhD U of Wisconsin Radiology, Medical Physics, and Pharmaceutics Novelos, Inc, Madison, WI Imaging in 2020 Jackson Hole, WY Oct 3, 2012 University of Wisconsin Paul

  2. Slide 2: Disclosure Statement

    Disclosure Statement Coinventor of CLR1404 technology and technical founder/CSO/Director of Novelos, Inc (Madison, WI) which owns all rights to CLR1404 and related technologies. NM404=CLR1404

  3. Slide 3: Improving Outcomes in Cancer Therapy

    Improving Outcomes in Cancer Therapy  Diagnosis – Sensitive, early detection and localization of primary tumors and metastases for disease staging and treatment planning  Therapy – Tumor kill and metastasis blockade while addressing phenotypic heterogeneity and cancer stem cells, all with low toxi

  4. Slide 4: Ether Cleavage Enzyme Activity in Normal Liver and Neoplastic Tissues

    Ether Cleavage Enzyme Activity in Normal Liver and Neoplastic Tissues a Tissues Host Animals Activity b Rat Liver Buffalo 7.3 b Morris Hepatoma 7794A Buffalo 5.8 b Morris Hepatoma 7777 Buffalo 1.4 c Sarcoma 180 HA/ICR 0.42 c Melanoma B-16 C57BL/6 0.31 c Ehrlich Ascites Carcinoma HA/ICR 0.14 c KHZ Ma

  5. Slide 5: PLE Structure Activity Relationships

    PLE Structure Activity Relationships X O O(CH2) CH3(CH2)16CO O + OPOCH2CH2N Me3 - O X=125,124,131I >30 analogs synthesized, radiolabeled, and evaluated Synthesis and Structure Activity Relationship Effects on the Tumor Avidity of Radioiodinated Phospholipid Ether Analogues. J Med Chem (2006) 49:2155

  6. Slide 6: Diapeutic Phospholipid Ether Analogs

    Diapeutic Phospholipid Ether Analogs Diapeutic moiety Targeting 131I‐CLR1404 124I‐CLR1404 CLR1401 CLR1502 CLR1501 Optical Molecular PET Imaging Cytotoxic Optical 800 nm Radiotherapy Chemotherapy 500 nm (Near IR) Phase 1b MTD Phase 1-2 Preclinical stage Preclinical stage Preclinical stage Complete sa

  7. Slide 7: PLE Tumor Imaging Agents

    PLE Tumor Imaging Agents ( PET/Therapy C L R 1 4 0 1 *= I-1 2 7 Chemo N M 4 0 4 *= I-1 2 4 PET C L R 1 4 0 4 *= I-1 3 1 Rad Therapy NIR (ex 780/em 800 nm) ( C LR 1502 Fluorescent ( C L R 1 5 0 1 (ex 495/em 515 nm) Indocyanine Bodipy Alkylphosphocholine Class

  8. Slide 8: Diapeutic CLR1404 Radiopharmaceutical

    Diapeutic CLR1404 Radiopharmaceutical ■ Small molecule simplicity and advantages ■ Stabile aromatic iodine resists in vivo deiodination ■ Can be radiolabeled with any iodine isotope ■ Iodine-124 (PET isotope with 4.2 day half-life) ■ Iodine-131 (SPECT and therapy isotope with 8 day half-life) ■ Iodi

  9. Slide 9: Tumor Imaging with 124I-CLR1404 PET

    Tumor Imaging with 124I-CLR1404 PET University of Wisconsin Paul P. Carbone Comprehensive Cancer Center

  10. Slide 10: CLR1404 Tumor Time Course

    CLR1404 Tumor Time Course 124I-CLR1404 in PC3 SCID Mouse Tail Head 6h 24h 48h 72h 120h µPET scans: Head down/tail up with flank tumor Fiducial markers (arrows) Tumor uptake evident in about 9h

  11. Slide 11: Inflammation: CLR1404 vs FDG PET

    Inflammation: CLR1404 vs FDG PET PC3 Prostate CA 18F-FDG 124I-CLR1404 I H I/T=4.8 T Tibia T 1h 24h 3D cine projection (I=carrageenan induced inflammatory lesion, H=heart, T=human PC3-prostate tumors, SCID mouse)

  12. Slide 12: CLR1404 PET/MRI U87 MG-nuRat

    CLR1404 PET/MRI U87 MG-nuRat 48h 2 mm tumor 72h 4.7T MRI

  13. Slide 13: Primary and Metastatic Pancreatic Cancer Images

    Primary and Metastatic Pancreatic Cancer Images First Demonstration of Spontaneous Liver Metastasis Imaging 3D Hybrid microPET/CT image of an anesthetized orthotopic BxPC3 pancreatic tumor- bearing Nude mouse 48h post iv administration of 124I- CLR1404, The presence of the M primary pancreatic tumor

  14. Slide 14: Pan Cancer Imaging with 124I-CLR1404

    Pan Cancer Imaging with 124I-CLR1404 Adrenal Pancreas Brain Bladder Prostate Prostate Prostate Colon (3) Colon Pancreas TN Breast COLON Prostate Breast Brain Sarcoma Human Colorectal Lung Met Primary+Mets in 52/54 xenograft and spontaneous models

  15. Slide 15: Radiotherapy or Diapeutic Potential of I-CLR1404

    Radiotherapy or Diapeutic 131 Potential of I-CLR1404 Prolonged Tumor Retention RL251 Adrenal CA University of Wisconsin Paul P. Carbone Comprehensive Cancer Center

  16. Slide 16: 131I-CLR1404 Kaplan-Meier Survival Results

    131I-CLR1404 Kaplan-Meier Survival Results Mouse tumor models-Single injection* 1.0 Ovarian CA 1.0 Colon CA I-127-CLR1404 1.0 Renal Cell CA 1.0 TN Breast I-127-CLR1404 I-131-CLR1404 I-127-CLR1404 I-131-CLR1404 I-131-CLR1404 0.8 0.8 0.8 0.8 0.6 0.6 0.6 0.6 Survival Survival Survival Survival 0.4 0.4

  17. Slide 17: 124/131I-CLR1404 Diapeutic Response

    124/131I-CLR1404 Diapeutic Response PET/CT time course of an LS180 colon CA xenograft bearing mouse injected D6 D10 simultaneously with a D1 D3 D5 mixture of 124,131I-NM404 (200 µCi each). Time course is from 3h to 10 days. Animal lost weight near the end of the study. Images are not normalized for

  18. Slide 18: CLR1501 Selectively Targets Cancer Cells

    CLR1501 Selectively Targets Cancer Cells Normal Cancer cell fibroblast NHF Co-cultured MES SA/Dx5 Uterine Mia Paca-2 Pancreatic SK704-skin A375 Melanoma HCT-116 Colorectal Ovcar-3 Ovarian U87MG Glioma CLR1501 incubated 24h with cells then washed 2X with PBS prior to z-stack confocal microscopy. All

  19. Slide 19: Lipid Rafts are Over-Expressed in Cancer Cells

    Lipid Rafts are Over-Expressed in Cancer Cells Prostate Prostate Pancreatic Pancreatic A549 NSCLC Intact Rafts MBCD Co-cultured Pretreatment Fibroblast vs A549 Decreased 60% Kidney NSCLC Kidney Lung CLR1501 is taken up by cells via “lipid rafts”, specialized regions of cell plasma membranes (= red;

  20. Slide 20: Glioma Tumor Margin with CLR1501

    Glioma Tumor Margin with CLR1501 TUMOR Tumor border with bright field and without bright field BRAIN 200 µm Fluorescence micrograph of 22T Glioma Margins: Confocal a brain section (20 µm) 24h Green stain: CLR1501 and Blue stain: post CLR1501 (1 mg, iv) Hoechst 33452 (nucleus) injection. 22T cell lin

  21. Slide 21: In Vivo NIR Optical Scanning with CLR1502

    In Vivo NIR Optical Scanning with CLR1502 Colorectal Carcinoma (HCT-116) 10 min 3h 6h 24h 30h 48h Injected with 1 mg of CLR1502. Monitored the intensity in vivo over time. The color reflects the intensity. At 48 hours, animals euthanized and organs excised and scanned ex vivo. The organs clockwise s

  22. Slide 22: Intraoperative Tumor Margin Illumination

    Intraoperative Tumor Margin Illumination CLR1502 96h post injection HCT116 Xenograft In vivo In vivo FluobeamTM) In vivo Post Partial Dissection Fluoptics (IVIS Spectrum) (Fluobeam)) (Fluobeam))

  23. Slide 23: Mouse Brain Tumor Illumination-Fluobeam

    Mouse Brain Tumor Illumination-Fluobeam T T Fluobeam Image of excised mouse brain Photograph of excised brain and tumor 96h post and GSC-derived tumor CLR1502 injection

  24. Slide 24: Cancer Stem Cell Paradigm

    Cancer Stem Cell Paradigm  Cancer stem cells have now been firmly associated with most if not all major cancer types.  Numerous recent reports confirm that cancer stem cells do exist and are chemotherapy resistant.  Glioma stem cells are also known to be up to 30% more radiation resistant relativ

  25. Slide 25: Cancer Stem Cell Isolation and Properties

    Cancer Stem Cell Isolation and Properties Isolation of Cancer Stem Cells Glioma Marker(s) Reference Lapidot et al. 1994 Leukemia CD34 Bonnet and Dick 1997 Singh et al., 2004 CD133 Brain Neurospheres Hemmati et al., 2003 Clark et al., 2007 Breast CD24, CD44 Al Hajj et al., 2003 O’Brien et al., 2007 C

  26. Slide 26: Glioma Stem Cell Results-Kuo Group

    Glioma Stem Cell Results-Kuo Group T Vehicle control NHA 1 NSC 1.3 99-T 6 99-CSC 8 Comparative uptake of 1501 in normal vs malignant cells CLR1401 1501 CD133+ Fused In vivo uptake and serial GSC regrowth (3wk) with 1501 Prolonged retention in GSCs NHA NSC U87 MG 22-CSC Cells pretreated with 1401 or

  27. Slide 27: CLR1404 Clinical Development-2012

    CLR1404 Clinical Development-2012  124I-PET Imaging Phase1-2 Clinical Trials (UW IND) – Lung Cancer (Traynor/Perlman) (Image and dose optimization) – Glioma/ Brain tumors or Mets (Image and dose optimization) – Multiple Tumor Protocol (Liu) (Image and dose optimization) • Pancreas • Breast • Prosta

  28. Slide 28: NSCLC Brain Tumor Metastasis with 124I-CLR1404

    NSCLC Brain Tumor Metastasis with 124I-CLR1404 3 Previously unknown brain mets were discovered with CLR1404 (5 mCi) in this lung cancer patient. 8 mm Treatment plan was altered because of this finding Movie  Extremely low background activity afforded tumor to brain ratio of >28 (3-5 typically consi

  29. Slide 29: Human CLR1404 Brain Tumor Imaging

    Human CLR1404 Brain Tumor Imaging Lung Mets CE-MRI 124I-CLR1404 FDG Recurrent Glioma Grade 3 CE-MRI 124I-CLR1404 124I-CLR1404/MRI

  30. Slide 30: Primary Human Glioma (Grade 4)

    Primary Human Glioma (Grade 4) CE-MRI CLR1404 PET MRI/PET BP Newly diagnosed GBM. CE-MRI (left), 48h 124I-CLR1404 PET (center), and fused PET/MRI image (right). Blood pool activity from venous sinus (BP). “NM404 PET shows heterogeneous avidity throughout the tumor, likely showing more uptake in viab

  31. Slide 31: CLR1404 PET vs F-DOPA PET

    CLR1404 PET vs F-DOPA PET T1-MRI PET T1-MRI PET 18F-DOPA Image of 124I-CLR1404 Image of Recurrent Glioma Recurrent Glioma JNM Cover Image-March, 2012 (Tumor uptake at 6h) Walter F, et al, J Nuc Med 2012 53:393-98. Surgical efficacy due to lack of tumor clearance?

  32. Slide 32: High Grade Astrocytoma Previously Resected and Radiated

    High Grade Astrocytoma Previously Resected and Radiated MRI demonstrated new small enhancing lesion (<1 cm) in posterior right temporal lobe/hippocampus T2-MRI PET PET/MRI Radiation changes also evident throughout right hemisphere on T2 FLAIR Blood Pool MRI. No 1404 uptake. PET/MRI PET

  33. Slide 33: Phase 1b MTD Patient SPECT

    Phase 1b MTD Patient SPECT SPECT/CT image of Phase 1b patient with colorectal cancer metastases to the liver (multiple) and lung 21 days post injection of 25 mCi of 131I-CLR1404 confirming prolonged tumor retention.

  34. Slide 34: Diapeutic Treatment Paradigm

    Diapeutic Treatment Paradigm Find-Treat-Follow Tumor 131I-CLR1404 Therapy Dose Injection Tumor Monitor Response Imaging 124I-NM404 Image Quantification/Dose Calculation PET Image

  35. Slide 35: The Diapeutic Cancer Treatment Paradigm

    The Diapeutic Cancer Treatment Paradigm A major goal of oncology today is to predict which patients will respond to a molecularly targeted drug. This is done by using biomarkers or imaging surrogates which are selective for the pathway or target of interest. Limitations still exist. The PLE based di

  36. Slide 36: PLE Delivery Platform Summary

    PLE Delivery Platform Summary  Unique preclinical tumor targeting and retention properties of CLR1404 appear to translate to primary and metastatic human cancers (lung and others?)  Optical and radioactive CLR1404 analogs target and undergo prolonged retention in glioma stem cells.  The longer ha

  37. Slide 37: Thank you!

    Thank you! Novelos Colleagues UW Students and Faculty UW Maria Dawson Lance Hall Carbone Cancer Center Jill Erwin Fred Lee Radiology Chris Blakley Perry Pickhart Medical Physics Dennis Tate Sharon Weber Human Oncology Jason Larrabee Anne Traynor WARF Brad Wallom Glen Liu Clinical Trial Group Angki K

  38. Slide 38: Supplemental Slides

    Supplemental Slides

  39. Slide 39: PC-3 Prostate Cancer MicroPET with 124I-CLR1404

    PC-3 Prostate Cancer MicroPET with 124I-CLR1404 Lymph Node Metastasis Tail Tail Primary Ax Node Met Ax Node Met Contralateral Head Head PET Scanning 48h post CLR1404 injection

  40. Slide 40: 124I-CLR1404 DMVC in PIRC Rat

    124I-CLR1404 DMVC in PIRC Rat B M A MicroCT MicroPET C Fused PET/CT Fused 2D microCT projection (A) and 124I-CLR1404 microPET image (B) and fused microPET/microCT image (C) of excised PIRC rat colon filled with 2% barium. Fiducial marker (M), Tumor (arrow)

  41. Slide 41: 124I-CLR1404 DMVC Luminal Flythrough

    124I-CLR1404 DMVC Luminal Flythrough Virtual Biopsy? with Dove/Amos-Landgraph

  42. Slide 42: Triple Negative Breast Cancer Images

    Triple Negative Breast Cancer Images 124I-CLR1404 microPET/CT image of a mouse with triple negative breast cancer (MB-231). Triple negative Breast Cancer • Estrogen receptor negative • Progesterone receptor negative • Her2 receptor negative • 15-20% of breast cancer patients have this form Doesn’t r

  43. Slide 43: 131I-NM404 Max Tolerable Dose in Rats

    131I-NM404 Max Tolerable Dose in Rats Human (70kg) Equiv Rad tox Rat Dose (mCi) dose (mCi) findings 0.5 150* None 2.5 750 None Slight platelet drop 4.0 1200 and recovery Grade 3 platelet 5.0 1500 drop and recovery Grade 4 platelet 7.0 2100 drop and death Normal rats, N=6 for each cohort * Anticipate

  44. Slide 44: MicroPET/CT Based 4D-Treatment Planning for IV Radiotherapeutics

    MicroPET/CT Based 4D-Treatment Planning for IV Radiotherapeutics: 124I-CLR1404 Siemens 2008 Inveon Image of the Year- World Molecular Imaging Congress

  45. Slide 45: 124I-CLR1404 MicroPET of Human Glioma Stem Cell Derived Brain Tumor

    124I-CLR1404 MicroPET of Human Glioma Stem Cell Derived Orthotopic Brain Tumor Excised Brain 24h after injection 48h after injection [Tumor/Brain]=5.4 [Tumor/Brain]=7.0 With Kuo and Clark

  46. Slide 46: Clinical Phase 1a Dosimetry Results-Therapy

    Clinical Phase 1a Dosimetry Results-Therapy  Eight patients enrolled; four cancer types; 10 mCi 131I-CLR1404  Zero drug attributable serious adverse events  Consistent distribution from patient to patient – increases safety profile  Distribution and elimination exactly as predicted from animal s

  47. Slide 47: Potential Uses for CLR1404 Analogs

    Potential Uses for CLR1404 Analogs ■ Diagnosis, characterization, and staging of tumor masses regardless of location ■ Guiding or in conjunction with Tomotherapy ■ Endo/Exo Radiotherapy Synergy ■ PET Guided Tomotherapy ■ Monitoring tumor response to therapies ■ Radiotherapy (Diapeutic) [131I, 125I,

  48. Slide 48: CLR1404 Summary

    CLR1404 Summary ■ Preclinical imaging has shown selective tumor uptake and prolonged retention in 52/54 tumor types in mice. ■ Preliminary radiotherapy results with 131I-CLR1404 in mice (>12 models) are very promising and show significant life extension. ■ Rat MTD studies suggest acceptable dosimetr

Cellectar Biosciences — Imaging in 2020 (Jackson Hole, WY) on 6ix